The detailed research outcomes confirmed interim findings, exhibiting steady kidney perform and sustained remedy impact greater than 18 months after the final dose of...
Practically 60% of sufferers with IgAN within the SPARTAN Examine achieved full remission when utilizing FILSPARI as first-line therapy SPARTACUS Examine, PROTECT open-label extension,...
